MiNK Therapeutics' Cancer Therapy Misses Primary Endpoint in Phase II, Cites Durable Survival in Subset
summarizeSummary
MiNK Therapeutics reported mixed Phase II trial results for its allo-iNKT cell therapy, agenT-797, in PD-1 refractory gastroesophageal cancer. The study notably failed to meet its primary endpoint of Overall Response Rate (ORR). However, the company highlighted positive secondary findings, including a 77% disease control rate and durable survival beyond 20 months in a subset of patients, with an induction strategy showing improved progression-free and overall survival. This outcome is critical for the small-cap biotech, especially following its recent 'going concern' warning, as missing a primary endpoint typically signals a significant setback and will likely lead to substantial stock volatility. Traders will be watching for clarity on the drug's future development path and the company's ability to secure necessary funding.
At the time of this announcement, INKT was trading at $14.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $71.5M. The 52-week trading range was $6.34 to $76.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.